AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.
  • AAM 2022 U.S. Generic and Biosimilar Medicines Savings Report
    NEW: 2022 U.S. Generic & Biosimilar Medicines Savings Report
    Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.
  • IQVIA White Paper: Pharmacy Discount Card Utilization and Impact
    Explosive Growth in Drug Discount Cards is a Symptom of a Broken System
    A new white paper from IQVIA shines light not only on the growth of these cards, but also on how much patients are unnecessarily spending on low-cost generic drugs.
  • Biosimilars Patient Resource Center
    Biosimilars Patient Resource Center
    Your one-stop-shop for everything patients and health care professionals need to know about biosimilar medicines. Check out helpful links and resources from the Biosimilars Council, the FDA and other organizations.
  • GRx+Biosims 2022 - Generics + Biosimilars Conference
    GRx+Biosims 2022
    Join us at the premier scientific and regulatory event for the U.S. generics and biosimilars industry featuring timely programming relevant to technical, regulatory, policy professionals. November 7-9, North Bethesda, Maryland.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.
  • Markup Madness
    Who’s Profiting from Your Prescription?
    Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.
  • GDUFA/BsUFA User Fees
    What Are GDUFA and BsUFA User Fees?
    Watch this this video to learn more about how the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Act (BsUFA) help to get more generic and biosimilar medicines to patients more quickly.
    Watch Video
  • 2021 state savings map
    Generic Medicines Are Saving Your State Billions
    In 2020, generic and biosimilar medicines saved America's patients $338 billion. Find out how much your state saved with our interactive savings map.

Our Brands and Campaigns

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.